Sells IXIARO, a Japanese encephalitis vaccine, to travelers and military customers, and develops, manufactures and sells other preventive vaccines for infectious diseases.
20-F for FY2025, filed Mar 17, 2026We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing…View ↗
We commercialize a portfolio of proprietary and differentiated traveler vaccines, which is composed of IXIARO (also marketed as JESPECT in…View ↗
We have established our own commercial operations in certain travel vaccine markets including the United States, Canada, the United…View ↗
Customers pay for the company’s vaccines and third-party products when they ship or are delivered. Valneva also earns license fees, royalties on licensees’ sales, milestone payments and fees for research services.
20-F for FY2025, filed Mar 17, 2026The Group mostly generates product sales revenues from the sale of its commercialized travel vaccines and from the sale of third-party…View ↗
The Group’s product sales contracts generally include one type of performance obligation. Revenue is recognized at the point in time when…View ↗
In most cases, Valneva sells its products through distributors. Valneva is acting as principal given that it controls such products before…View ↗
The Group generates other revenues from its products, product candidates, and proprietary technologies. The contracts in place often…View ↗
EUR 174.7M
20-F for FY2025, filed Mar 17, 2026
EUR 174.7M ↗
Private and government customers, including the U.S. military, buy through Valneva’s own sales operations in some markets; elsewhere, specialist partners distribute its vaccines. Most product sales go through distributors, while sales to retailers and the U.S. Department of Defense are direct.
20-F for FY2025, filed Mar 17, 2026We have established our own commercial operations in certain travel vaccine markets including the United States, Canada, the United…View ↗
We manage nearly all of our global product sales revenues through our own commercial operations. Local operations include expertise in…View ↗
The Group’s product sales contracts generally include one type of performance obligation. Revenue is recognized at the point in time when…View ↗
In most cases, Valneva sells its products through distributors. Valneva is acting as principal given that it controls such products before…View ↗
Shrinking. Revenue fell 50% in 4 years, from EUR 348.1M in FY2021 to EUR 174.7M in FY2025, about 16% a year.
Chikungunya vaccine commercialization
The older report described a chikungunya vaccine candidate in clinical development; the latest describes a marketed chikungunya vaccine alongside Valneva’s traveler vaccines.
20-F for FY2022, filed Mar 30, 2023 20-F for FY2025, filed Mar 17, 2026VLA1553 – a vaccine candidate against the chikungunya virus, or CHIKV, a mosquito-borne virus that has spread to more than 100 countries…View ↗
Competes with Biken, Kaketsuken, Chengdu, Sanofi, Substipharm, Moderna, Ixodes, Takeda Pharmaceuticals, Tonix Pharmaceuticals, Inovio Pharmaceuticals, Tarsus, Euroimmun, GlaxoSmithKline, Baxter, Beijing Zhifei Lvzhu, Institut Pasteur, and GVGH
20-F for FY2025, filed Mar 17, 2026Given the large population in the Japanese encephalitis endemic region, consisting of over 3 billion people, and the inclusion of the…View ↗
Loading...